Abstract: Acute pulmonary embolism (PE) is a common clinical condition with presentations that may vary from asymptomatic subsegmental emboli to massive vascular obstruction and shock with high risk of death. Identifying patients at highest risk for death is critical to select those who would benefit most from thrombolytic therapy. New and evolving clinical prediction models, serum tests, and imaging modalities are being used to improve our ability to identify potential thrombolytic candidates. We review the evolution of the present guidelines on the management of PE, specifically regarding the evolving role of thrombolytics; outcomes following thrombolytic therapy, including mortality, hemorrhage, hemodynamic improvement, and prevention of chronic thromboembolic pulmonary hypertension; and our strategy for risk stratification of pulmonary embolism.
P
hysicians managing acute pulmonary embolism (PE) have a number of therapeutic options from which to choose, ranging from mechanical devices to intravenous anticoagulants and thrombolytics. Given the bleeding risks associated with thrombolytic therapy, a working knowledge of the evidence regarding patient selection for thrombolysis in acute PE is essential for managing this disease in a timely and accurate fashion.
The reported annual incidence of venous thromboembolism (VTE) is 23 to 69/100,000 cases per year, 1,2 with one-third of those presenting with acute PE. 3 Presentations vary from incidentally found, asymptomatic subsegmental emboli to massive vascular obstruction and shock, with mortality ranging from G1% to as high as 60%. 4 Rapid and accurate identification of patients at highest risk for death is crucial to correctly deliver thrombolytics to those in whom the benefits outweigh the risks. This article reviews the current US and European guidelines for the use of thrombolytics and the predictors of adverse outcomes in acute PE.
Evolution of the Definitions of PE Severity
In 2000, the European Society of Cardiology (ESC) developed a guideline to characterize PE by disease burden, classifying patients into ''massive'' and ''nonmassive'' PE (Appendix 1). The society defined massive PE as PE with shock or hypotension, defined as a systolic blood pressure (SBP) of G90 mm Hg or a drop of 40 mm Hg for 915 minutes not caused by new-onset arrhythmia, hypovolemia, or sepsis. They further subdivided the group that did not meet criteria for massive PE into submassive PE and nonmassive PE. Submassive PE was defined as acute PE with evidence of right ventricular (RV) strain without evidence of shock, whereas emboli with no shock or evidence of RV strain were considered nonmassive. The society hypothesized that hemodynamic consequences of PE are directly related to the size and number of PE. 5 In 2008, the ESC reconvened and proposed an update and reclassification of their guidelines. They proposed the terms ''high risk,'' ''intermediate risk, ' ' and ''low risk'' to replace massive, submassive, and nonmassive, and emphasized that the prognosis of PE depends on hemodynamic instability caused by recurrent embolization and deterioration of RV function in the first 24 to 48 hours rather than the amount of pulmonary artery obstruction. 6 In 2011, to further clarify the role of advanced therapies in the management of VTE, the American Heart Association (AHA) produced a classification of PE severity (Appendix 2). They defined massive PE as acute PE with shock as defined similarly by the ESC, but also included pulselessness or persistent, profound bradycardia (defined as heart rate G40 bpm) in their definition of shock. They defined submassive PE as acute PE without systemic hypotension but with the presence of RV dysfunction (RVD) or laboratory evidence of myocardial necrosis. They chose to characterize the ESC's nonmassive PE group as low-risk PE defined as acute PE in the absence of clinical markers or adverse prognosis as defined in massive or submassive PE (Table 1) . 7 The 2012 American College of Chest Physicians (ACCP) updated their VTE guidelines but did not use specific terms to define the severity of PE (Appendix 3). 8 Role of Thrombolysis in Management of Massive PE/High-Risk PE Ten percent of all of the diagnosed cases of PE meet the definitions of high risk or massive PE. 9 Short-term mortality associated with massive/high-risk PE in untreated patients is as high as 60%. 4 Massive/high-risk PE typically is diagnosed by clinical presentation and multidetector computed tomography (MDCT); however, if suspicion for PE is high and MDCT is not available or the patient is too hemodynamically unstable to transfer for MDCT, European guidelines recommend bedside echocardiography to assess RVD and consider for thrombolysis if identified (class I recommendation, level of evidence: C). 6 Although no clinical trials have directly addressed the clinical outcomes of massive PE, subsets of trials demonstrate more rapid improvement in hemodynamic status in thrombolysis over heparin. 10Y14 A subset of a meta-analysis concluded that thrombolysis had a benefit over heparin for the composite outcome prevention of recurrence or death (9 16, 17 experts have called for a reexamination of the use of thrombolytics in this higher-risk subgroup.
In 1993, Goldhaber et al 10 performed a randomized trial of 101 hemodynamically stable patients with acute PE to assess the effect of thrombolysis and heparin versus heparin alone on RV function and on pulmonary artery perfusion. They found more rapid improvement in RV function (39% vs 17%; P = 0.005) and pulmonary artery perfusion (14.6% vs 1.5%; P G 0.0001) at 24 hours with thrombolysis. They also showed a decrease in recurrent PE (0% vs 9%; P = 0.06) with thrombolysis after 14 days. 10 In 2002, a large randomized trial of patients with submassive/intermediate-risk PE conducted by Konstantinides et al 18 showed a significant decrease in adverse events, requiring escalation in management within 30 days of acute PE with recombinant tissue-plasminogen activator (rt-PA) plus heparin compared with heparin alone (10.2% vs 34%; P = 0.004). No significant difference in mortality (3.4% vs 2.2%; P = 0.71) and PE recurrence (3.4% versus 2.9%; P = 0.89) was noted. Also, rt-PA was not associated with an increased risk of major bleeding (0.8% vs 3.6%; P = 0.29) in this study. 18 In 2009, a meta-analysis that included both of the above studies confirmed a lack of mortality benefit of rt-PA over heparin in patients with hemodynamically stable PE (3.5% vs 4.6%, relative risk 0.97, 95% CI 0.38Y2.51; P = 0.73). Again, the meta-analysis did not show an increased risk of major bleeding with the use of rt-PA (4.9% vs 4.6%, relative risk 0.94, 95% CI 0.39Y2.27; P = 0.61) ( Many questions remain, especially regarding the role of thrombolytics in the prevention of chronic thromoembolic pulmonary hypertension (CTEPH). Although 950% of patients have detectable thromboemboli at 6 months after diagnosis of acute PE, 20 7% of patients with submassive/intermediate-risk PE have evidence of persistently elevated RV pressure by echocardiogram 6 months later 21 ; however, only 3% of all patients with PE will develop symptomatic CTEPH. 22 Whether immediate thrombolysis can prevent this uncommon but significant morbidity to offset the known bleeding risks is being hotly debated. 23, 24 Guidelines by the ESC and the AHA for the management of submassive/intermediate-risk PE suggest thrombolysis in selected cases in whom there is not an elevated risk of bleeding. 6, 7 (AHA guidelines: class IIb, level of evidence: C; ESC guidelines: class IIb, level of evidence: B). The revised 2012 ACCP guideline recommends thrombolysis ''in selected patients with acute PE not associated with hypotension and with a low risk of bleeding whose initial clinical presentation or clinical course after starting anticoagulation therapy suggests a high risk of developing hypotension'' (grade 2C recommendation). The guideline does not specify how to identify those at high risk for hypotension. 8 Although there is no mortality benefit to thrombolysis in intermediate-risk PE, there is immediate improvement in pulmonary hemodynamics and RVD. It is also notable that there is no increase in fatal bleeding risk with rt-PA versus heparin in large meta-analyses. Whether this translates into lower risks of CTEPH is an important question for future studies.
Risk Stratification in PE
Early risk stratification of PE is crucial to identify candidates for thrombolysis because these patients are at highest risk of death. 25 We review the current prognostic evidence of all of the available clinical, laboratory, and radiological markers below. 
Clinical Markers
Hemodynamic status and underlying comorbid disease are independent risk factors associated with 30-day mortality. 26 Hemodynamic instability is defined as SBP G90 mm Hg, a decrease in SBP by 940 mm Hg for more than 15 minutes, or positive shock index. Shock index is defined as the cardiac rate divided by SBP, with a positive index as any value Q1. Compared with SBP G90 mm Hg, the shock index is more sensitive for mortality at 1 month (30% vs 8%) but less specific (86% vs 96%) in one study of a registry of PE patients. The hazard ratio (HR) for shock index was 2.3 (95% CI 1.5Y3.6P G 0.001) and for SBP G90 mm Hg the HR was 1.7 (95% CI 0.9Y3.2; P = 0.08) ( Table 3) . 27 Risk stratification for underlying comorbid clinical conditions can be performed by using the Pulmonary Embolism Severity Index. The index includes 11 clinical criteria incorporated into a predictive model that has been shown to be a valid predictor of 3-month mortality when low-risk scores (classes I and II) are compared with highYrisk scores (classes IIIYV), with a sensitivity and specificity of 96% and 47%, respectively (Tables 4 and 5 ). Cancer is an important clinical risk factor and comorbidity associated with PE. According to one study, immediate angiographic response to thrombolysis was similar in 57 patients with cancer compared with 254 patients without cancer (77% vs 73%; P = 0.65); however the extent of reperfusion was attenuated at 24 hours in patients with cancer (6% vs 13%; P = 0.007). Furthermore, major bleeding was not increased in patients with cancer compared with patients without cancer (12% vs 21%; P = 0.12). 29 Other authors have shown that thrombolytics can be safely used without significant bleeding complications in catheter-directed thrombolysis 30 and to treat occluded catheters. 31 This evidence suggests that thrombolysis carries similar risks and benefits in patients with and without cancer and may be safely used in acute PE. For chronic therapy, patients with cancer may benefit from long-term heparinoids over vitamin K antagonists. 8 
D-Dimer
The risk of mortality increases with increase in serum D-dimer level. According to one prospective study of 366 patients, predicted mortality within 3 months with D-dimer G1500 Kg/L is 1.1%, which increases to 9.1% with a D-dimer level 95500 Kg/L. Sensitivity and specificity of D-dimer level G1500 Kg/L to predict low mortality is 95% and 26%, respectively, whereas sensitivity and specificity of D-dimer level 95500 Kg/L to predict high mortality is 42% and 77%, respectively (OR 4.1, 95% CI 1.1Y73.5; P not reported). 32 Specificity for D-dimer in elderly patients, patients with recurrent VTE, and patients with cancer is low. 33 Although D-dimer is a highly valuable tool for the diagnostic evaluation of low and intermediate-risk PE, it does not yet have a role in the risk stratification of PE. 6 B-Type Natriuretic Peptide and Pro-BNP B-type natriuretic peptide (BNP) and pro-BNP are associated with ventricular stress. 34 A systemic review and metaanalysis showed that elevated levels of BNP and pro-BNP were significantly associated with in-hospital mortality. 35 Sensitivity of BNP (using cutoffs of 75Y100 pg/mL) to predict in-hospital mortality in a meta-analysis of 4 studies was 85%, whereas specificity was 43% (OR 6.5, 95% CI 2.0Y21; P = 0.002). For pro-BNP (using cutoffs of 600 pg/mL in 2 studies, 1000 pg/mL in 2 studies), sensitivity was 95% with a specificity of 56% (OR 8.7, 95% CI 2.8Y27; P = 0.0002) for in-hospital all-cause mortality. 35 BNP and pro-BNP were found to correlate with RVD as determined by echocardiogram. 36 Although these markers are not useful as individual risk-stratifying markers because of their low specificity and low positive predictive value, some authors argue that they can be useful in risk stratification by combining them with echocardiographic findings of RVD. 37 
Serum Troponin
According to a meta-analysis that used a wide range of troponin I cutoffs (90.1 Y 92.0) and troponin T cutoffs (90.01 Y 90.1), sensitivity was 70% and specificity was 72% for predicting in-hospital mortality (OR 5.24, 95% CI 3.28Y8.38; P G 0.01). 38 Although studies in this meta-analysis used a wide range of cutoffs, the AHA guidelines recommend using troponin I of 90.4 and troponin T of 90.1 to identify RVD. 7 A prospective study using troponin, BNP, and echocardiogram found that troponin was not independently correlated with 30-day mortality when other covariables were controlled. 26 
Electrocardiogram
According to a study on 508 patients with massive or submassive PE from a large prospective registry, electrocardiogram (ECG) findings of RV strain were an independent predictor of 30-day mortality (29% vs 11%; Table 3 ). Sensitivity and specificity of various ECG findings to predict 30-day mortality ranges from 15% to 50% and 60% to 90%, respectively. Although no single finding on ECG is independently associated with adverse outcomes, the presence of any one of the group of the above ECG findings predicted 30-day mortality (OR 2.56, 95% CI 1.49Y4.57; P G 0.001). 39 
RVD by Imaging
Most deaths from high-risk or intermediate-risk PE are associated with RVD. 40 Recent studies correlating RVD findings by echocardiogram as well as MDCT scan have been shown to predict short-term prognosis in acute PE.
Findings of RV strain pattern on echocardiography include RV dilatation and hypokinesis, flattening or paradoxical movement of interventricular septum toward the left ventricle, pulmonary hypertension, tricuspid regurgitation, and inspiratory collapse of the inferior vena cava. 41 Unfortunately, there is a lack of consensus on the standardization of these criteria. 42 Post hoc analysis of 1035 hemodynamically stable patients with PE in the International Cooperative Pulmonary Embolism Registry study demonstrated that RV hypokinesis detected by echocardiography is an independent risk factor for 30-day mortality, with sensitivity of 52% and specificity of 62% (OR1.94, 95% CI 1.23Y3.06; P not reported). 43 A retrospective study of 950 patients from a large French registry showed that an RV/LV (left ventricle) end-diastolic diameter ratio of Q0.9 was an independent risk factor for in-hospital mortality, with sensitivity of 72% and specificity of 58% (OR 2.66, 95% 44 Specificity of RVD by echocardiography as a prognostic marker can be improved by combining it with biomarkers of myocardial injury. 45 RV dilatation also can be detected by MDCT. In a retrospective study of 454 patients with acute PE, 30-day mortality rate was found to be 15% with RVD detected by MDCT (defined as an RV/LV ratio of 90.9) versus 7.7% without RVD identified. 46 Sensitivity and specificity of CT findings of RVD from this study are 78% and 38%, respectively (HR 5.17, 95% CI 1.63Y16.35; P = 0.005). Although MDCT can provide anatomic information and diagnosis simultaneously, one disadvantage of MDCT over echocardiogram is that MDCT can only assess RV size but cannot determine other dynamic parameters such as hypokinesis of the RV wall. 36 Suggested Prognostic Strategy for Clinical, Laboratory, and Radiological Markers
The following outlines our suggested management strategy for acute PE (Fig.) 3. Given that echocardiograms are not highly sensitive for predicting short-term mortality, the ESC recommends against routinely ordering them for hemodynamically stable patients (ESC guidelines: class III, level of evidence: C). 6 In light of the 2011 AHA guidelines, however, we believe that patients with elevated clinical or biochemical markers would benefit from the additional prognostic information obtained from echocardiography. Unfortunately, urgent echocardiogram is not available at every hospital, which is a major limitation for this recommendation. 4. Thrombolytic therapy comes with both significant cost (US $2300) and bleeding risk, and physicians should consider all risks and benefits to intermediate-risk patients given the absence of proven mortality benefit.
Contraindications of Thrombolytic Therapy
The contraindications of thrombolytic therapy 47 (Table 6 ) for PE are the same as those used for contraindications for patients with acute myocardial infarction.
Future of Acute Pulmonary Thromboemboli Management
The role of thrombolysis in submassive/intermediate-risk PE remains a topic of debate. Although individual clinical and laboratory markers are too nonspecific to predict outcomes, combinations of these predictors may better identify those thrombolysis candidates who may gain short-term mortality benefits and long-term prevention of CTEPH. 37 New biomarkers for PE risk stratification, including heart-type fatty acidYbinding protein and growth differentiation factor-15 may provide additional prognostic information. 48 Given that bleeding from thrombolysis is the most limiting complication, dose reduction and alternative thrombolytics are being investigated. A randomized controlled trial showed equal efficacy in terms of improvement in RVD, lung perfusion and pulmonary artery obstruction, and fewer bleeding complications with alteplase 50 mg as compared with the presently used 100-mg dose. 49 Alternative thrombolytics such as reteplase and tenecteplase are also being studied. 34 A large, multicenter, international, double-blind, placebocontrolled trial (NCT00639743), the Pulmonary Embolism International Thrombolysis trial, began enrolling subjects in 2007 and will involve 1000 patients in 12 countries. The study will compare tenecteplase plus standard anticoagulation with standard anticoagulation alone for submassive PE, with a primary endpoint of hemodynamic collapse and mortality at 7 days. Completion of the trial is expected around 2013.
Conclusions
PE is a common, important diagnosis with a wide range of clinical outcomes. The identification of patients with the highest risk of death who are candidates for thrombolytic therapy is essential. Clinical markers, biomarkers, and radiological techniques assist in identifying patients without overt hypotension, and combinations of these may improve our future diagnostic accuracy. More study is needed to determine long-term prognosis, including persistence of abnormal pulmonary hemodynamics, in patients treated with and without thrombolysis. 
